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Abstract: Hypersensitivity diseases caused by nonsteroidal anti-
inflammatory agents are relatively common in the population. This
article summarizes the present understanding on the various allergic
and nonallergic clinical pictures produced through hypersensitivity to
these drugs using the pathogenic classification of hypersensitivity
reactions recently proposed by the Nomenclature Committee of the
World Allergy Organization to guide clinicians in the diagnosis and
management of patients with these conditions.
Key Words: aspirin, drug hypersensitivity, nonsteroidal
anti-inflammatory drugs, NSAIDs
(WAO Journal 2008;1:29Y33)
A large proportion of the population is exposed to non-steroidal anti-inflammatory drugs (NSAIDs) worldwide
from either medical prescription or self-medicated.1 It is then
not surprising that these drugs constitute the second major
cause of hypersensitivity reactions to drugs after A-lactamic
antibiotics.
The prevalence of these reactions in the population
varies between 0.1% and 0.3%,2 and therefore, it is very
important for clinicians to recognize and properly treat
patients suffering from NSAID hypersensitivity. This article
reviews the information presently available on the clinical
manifestations, diagnosis, and management of these reactions.
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Pharmacology textbooks define NSAIDs as compounds
that antagonize inflammation through the inhibition of a group
of enzymes known as cyclooxygenases (COXs).3 Some drugs,
notably pyrazolones and acetaminophen, were previously not
classified into this group because they did not inhibit COX
enzymes. In recent years, new COX isoenzymes have been
described, such as COX-2b and COX-3, that can be selectively
antagonized by these drugs, and therefore they would fit into
the NSAID category.4,5
Classic NSAIDs that inhibit both major COX isoen-
zymes, COX-1 and COX-2, can be classified according to
their chemical structure as depicted in Table 1. A second
classification is based on the selectivity of NSAIDs for
inhibition of COX isoenzymes (Table 2).
CLINICAL SPECTRUM AND PATHOGENESIS
A wide variety of clinical manifestations can be
produced by NSAIDs. Using the classification proposed by
the Nomenclature Committee of the World Allergy Organiza-
tion,6 the following types of hypersensitivity reactions can be
considered:
Allergic Hypersensitivity
Immunologic reactions to NSAIDs can be subdivided
into immediate (mediated by immunoglobulin E [IgE]) and
delayed (mediated by lymphocytes).
Immediate Reactions
Urticaria and Angioedema
Immunoglobulin EYmediated cutaneous reactions have
been described for pyrazolones,7 acetaminophen,8 and aspirin.9
Allergic Anaphylaxis
Reported for ibuprofen,10 ketorolac,11 indomethacin,
sulindac, zomepirac,12 fenoprofen, meclofenamate, naproxen,
piroxicam, tolmetin,13 glafenine, acetaminophen, aspirin, di-
clofenac, and celecoxib.14
Delayed Reactions
These include cell (T lymphocyte)-mediated type IV
hypersensitivity reactions involving specific organs and
systems.
Skin Diseases
Fixed-drug Eruptions. Characterized by erythematous plaques
recurring in the same anatomical site in every occasion the
drug is administered. Metamizole, piroxicam, phenylbuta-
zone, paracetamol, aspirin, mefenamic acid, diclofenac,
indomethacin, ibuprofen, diflunisal, naproxen, and nimesulide
have been incriminated.15
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and
Acute Generalized Exanthyematous Pustulosis (AGEP).
These serious skin reactions belong to the erythema multi-
forme spectrum of bullous eruptions and can be associated
with NSAIDs.16
Stevens-Johnson syndrome (SJS) is a severe diffuse
mucocutaneous eruption causing erythematous or purpuric
macules, blisters, or target lesions with no more than 10% skin
detachment, accompanied by systemic manifestations, occur-
ring 1 to 8 weeks after administration of incriminated
medications.17 Toxic epidermal necrolysis (TEN) involves
30% or more skin detachment, whereas between 10% and 30%
detachment is applied to the term SJS-TEN overlap syndrome.
Among NSAIDs, oxicams, phenylbutazone, and oxy-
phenbutazone have been responsible more often.16,18
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Recently, a great deal of attention has been given to the
association of SJS/TEN with the use of new COX-2 inhibitors,
especially valdecoxib and celecoxib.19Y21
Acute generalized exanthematous pustulosis is a rare
condition characterized by a rapid-onset pustular eruption
involving most of the body. Typical lesions are generalized,
nonfollicular, pinhead-sized sterile pustules on an erythema-
tous background that are associated with fever and
neutrophilia.22 Histopathologic features include papillary
edema, a mixed upper dermal perivascular infiltrate, and a
spongiform subcorneal pustule. Activated HLA-DRYpositive
CD4 and CD8 T cells, interleukin-8, interleukin-5, and
granulocyte-macrophage colony-stimulating factor are present
in the tissue. The NSAIDs associated with acute generalized
exanthematous pustulosis more often are ibuprofen, phen-
ylbutazone, naproxen, acetylsalicylic acid, valdecoxib, and
celecoxib.
Contact and Photocontact Dermatitis. Contact with NSAIDs
can induce itchy, erythematous, edematous, and vesicular
lesions, and photocontact dermatitis, an exaggerated or
abnormal cutaneous response to light. Among NSAIDs,
diclofenac, indomethacin, flurbiprofen, bufexamac, etofena-
mate, flufenamic acid, ibuprofen, ketoprofen, and tiaprofenic
acid are the most common inducers of contact dermatitis.
Cross-reactivity between some chemically related NSAIDs
has been observed.23
Maculopapular Eruptions. Virtually all NSAIDs are able to
produce maculopapular eruptions, one of the most common
cutaneous adverse effects of NSAIDs. Ibuprofen, pyrazolones,
flurbiprofen, diclofenac, and celecoxib have been more
frequently involved.
Pneumonitis
Some NSAIDs such as aspirin, sulindac, ibuprofen, and
naproxen can induce allergic pneumonitis. The NSAID-
induced pneumonitis can be suspected from a temporal
relationship between lung infiltrates and drug administra-
tion.24 Most patients will improve after drug discontinuation,
although corticosteroids may be needed for severe or persis-
tent cases.
Aseptic Meningitis
The NSAIDs are the medications more often involved in
the production of drug-induced meningitis. Clinical features
include fever, headache, photophobia, neck stiffness, nausea,
vomiting, arthralgia, myalgia, rash, and abdominal pain.25
Ibuprofen, sulindac, naproxen, tolmetin, diclofenac, ketopro-
fen, piroxicam, indomethacin, rofecoxib, and celecoxib have
been associated with aseptic meningitis. Casas-Rodriguez
et al26 observed that 61% of ibuprofen-related meningitis
occurred in patients with connective tissue diseases, mainly
systemic lupus erythematosus. Management includes drug
withdrawal, systemic corticosteroids, and avoidance of re-
exposure to drugs from the same family as the causal drug.
Nephritis
Rarely, in aged patients with normal kidneys, NSAIDs
may trigger a spectrum of nephritides (BNSAID nephro-
pathy[), including tubular, interstitial, acute or subacute
tubulointerstitial nephritis, chronic interstitial nephritis with
papillary necrosis, and tubulointerstitial nephritis combined
with nephrotic syndrome. The NSAIDs may also produce
glomerulopathies such as minimal change nephropathy,
membranous glomerulonephritis, and focal sclerosis.27,28
Hepatitis
Rarely, NSAIDs, among them niflumic acid, tolfenamic
acid, diclofenac, fenoprofen, ibuprofen, indomethacin,
naproxen, piroxicam, pirprofen, and sulindac, induce allergic
hepatitis that can be mixed, cytolytic, or cholestatic. It is
observed in elderly women taking multiple medications.29
Herdeg et al30 reported a case of metamizole-induced
allergic cholestatic hepatitis characterized by generalized
exanthema and increased liver enzymes. Sensitization to the
drug was confirmed by means of lymphocyte transformation
test.
Nonallergic Hypersensitivity
Composed of manifestations at the respiratory tract and
skin, and nonallergic anaphylaxis.
Respiratory Hypersensitivity
Aspirin-induced asthma, aspirin-intolerant asthma, or
aspirin-exacerbated respiratory disease (AERD) is characterized
by asthma, rhinosinusitis, nasal polyposis, and aspirin/NSAID
TABLE 1. Chemical Classification of NSAIDs
Chemical Group Drugs
Alkanones Nabumetone
Anthranilic acids (fenamates) Meclofenamic acid, mefenamic acid
Arylpropionic acids Fenoprofen, flurbiprofen, ibuprofen,
ketoprofen, naproxen, oxaprozin
Enolic acids Oxicams (piroxicam, tenoxicam),
pyrazolidinediones (oxyphenthatrazone,
phenylbutazone)
Heteroaryl acetic acids Diclofenac, ketorolac, tolmetin
Indole and indene acetic acids Etodolac, indomethacin, sulindac
Para-aminophenol derivatives Acetaminophen (paracetamol)
Pyrazol derivatives Aminopyrine, antipyrine, dipyrone
Salicylic acid derivatives Aspirin, choline magnesium trisalicylate,
diflunisal, olsalazine, salicylsalicylic
acid, salsalate, sodium salicylate,
sulfasalazine
TABLE 2. Classification of NSAIDs According to Their
Selectivity for COXs
Selectivity Drugs
Weak COX inhibitors Acetaminophen, salsalate, salicylamide,
sodium salicylate, choline-magnesium trisalicylate
COX-1/COX-2
inhibitors
Piroxicam, indomethacin, sulindac, tolmetin,
ibuprofen, naproxen, fenoprofen, meclofenamate,
mefenamic acid, diflunisal, ketoprofen, diclofenac,







Celecoxib, rofecoxib, valdecoxib, parecoxib,
etoricoxib, lumiracoxib
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hypersensitivity. Asthmatic reactions induced by NSAIDs occur
in 5% to 20% of adult asthmatic patients.31 The pathogenesis
seems to involve the combined effects of chronic inflammation
and a pharmacogenetic abnormality of arachidonic acid
metabolism in response to NSAIDs. This leads to sulfidoleuko-
triene overproduction and to a decrease in anti-inflammatory
prostaglandin E2 from insufficient COX-2 activation, leading to
additional leukotriene synthesis.32,33 Excellent reviews on this
topic have been recently published.34
Cutaneous Hypersensitivity
The cutaneous pattern of NSAID-induced cross-
reactions includes cross-reacting urticaria and angioedema
in patients with or without chronic idiopathic urticaria
(CIU) (Fig. 1). The mechanisms are not completely under-
stood, but in patients with CIU, COX-1 inhibition has been
demonstrated.35,36
Nonallergic Anaphylaxis
Previously known as anaphylactoid or pseudoallergic
reaction, it is observed in cross-reactive patients and pre-
sumably mediated by inhibition of COX-1.37
DIAGNOSTIC METHODOLOGY FOR ADVERSE
REACTIONS INDUCED BY NSAIDS
The choice of diagnostic tests is based on the clinical
picture and possible pathogenesis.
Reactions Mediated by IgE
Although intradermal injection of pyrazolones has
been proposed for diagnostic purposes, no correlation with
the clinical picture was observed.7 Presently, no standardized
reagents for immediate-type skin tests with NSAIDs are
available.
Delayed-type Reactions
Patch tests constitute a simple, fast, and relatively safe
method for the diagnosis of delayed reactions to NSAIDs. For
fixed-drug eruptions, lesional skin should be used for the
test.38Y40 When photoallergy is suspected, photopatch tests are
indicated.41 Concentrations of NSAIDs commonly used for
patch tests are summarized in Table 3.
It must be noticed that in some cases, a rechallenge with
the drug is not recommended because of the high risk of severe
and generalized reactions.42 Intradermal and scratch tests with
reading at 48 and 72 hours have also been used to confirm
delayed hypersensitivity to NSAIDs.43
The lymphocyte transformation test measures the in
vitro proliferative response of T cells stimulated by the drug.
Although this test is worth to be considered, it is only available
in some laboratory facilities in specialized centers.44
Nonallergic Reactions
For respiratory and cutaneous cross-reactions, the
criterion standard continues to be the controlled oral
provocation test carried out in the appropriate medical
facilities by physicians experienced in this kind of test and
with easy access to medications and equipments necessary for
the treatment of reactions.45,46 Bronchial and nasal inhalation
challenges with aerosols of L-lysine acetylsalicylic acid have
also been used.47,48 An algorithm for the diagnosis and
FIGURE 1. A 62-year-old man with CIU exacerbated by the
ingestion of sodium diclofenac.



























WAO Journal & Volume 1, Number 2, February 2008 NSAID Hypersensitivity
* 2008 World Allergy Organization 31
management of patients with cutaneous NSAID reactions has
been proposed.46
De Weck et al49 have developed 2 in vitro assays done
with blood basophils: the leukotriene release test and the
basophil activation test. These tests require, however, special
equipments and reagents, including a flow cytometer, and
therefore are more expensive and limited to some centers.50
PATIENT MANAGEMENT
IgE-mediated Reactions
Patients reacting to a single NSAID can receive NSAIDs
from a different chemical group (see Table 1). In general, it is
recommended not to use in these patients NSAIDs from the
same group because cross-reactions between NSAIDs of
similar chemical structure occur.
Delayed-type Reactions
Discontinuation of offender medication and pharmaco-
logical treatment with corticosteroids and antihistamines are
recommended.
Patients with severe reactions of the TEN/SJS type
should be transferred to intensive care or burn units. In-
travenous immunoglobulins have been used in patients with
TEN, based on its content of natural anti-Fas antibodies, and a
reduction of mortality has been shown in some studies.51
Systemic therapy with infliximab (antiYTNF->) induced rapid
improvement of skin lesions in patients with TEN.52
Nonallergic Reactions
Aspirin-exacerbated Respiratory Disease
The following measures are recommended for patients
with AERD:
& Avoidance of all classic COX-1 inhibitors.
& Pharmacological treatment with topical and systemic
corticosteroids, leukotriene receptor antagonists, and
5-lipoxygenase inhibitors, antibacterials, and antifungals.53
& Use of alternative NSAIDs (acetaminophen, salsalate,
dextropropoxyphene, opioids, ergotamine, hyoscine, sodium
salicylate, salicylamide, choline-magnesium trisalicylate,
floctafenine). Acetaminophen and other weak inhibitors of
COX-1 are generally well tolerated by these patients at
lower doses, but if the dose is increased, respiratory reactions
can occur.54
& Specific COX-2 inhibitors are tolerated by most patients
with AERD.55
& Desensitization is indicated for selected sensitive patients
who need to receive NSAIDs for other medical conditions
and for patients with severe corticosteroid-dependent
AERD.56
Cutaneous Reactions and Nonallergic Anaphylaxis
Patients with cross-reacting urticaria/angioedema and
nonallergic anaphylaxis should be managed as follows:
& Avoidance of COX-1 inhibitors.
& Alternative medications as mentioned above (see aspirin-
exacerbated respiratory disease).
& COX-2 inhibitors are safe for most of these patients, but
long-term use of coxibs is not recommended because of the
cardiovascular risks associated with them. In such cases,
preferential inhibitors of COX-2 may be helpful.57,58
& Desensitization is generally not recommended.
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